NCT06082934View on ClinicalTrials.gov

Olverembatinib Plus Venetoclax and Dexamethasone for Treatment-naïve Ph+ Acute Lymphoblastic Leukemia

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

November 1, 2026

Study Completion Date

November 1, 2026

Conditions
Newly-diagnosed Ph+ Acute Lymphoblastic Leukemia
Interventions
DRUG

Olverembatinib plus venetoclax and dexamethasone

Olverembatinib: orally every other day at a dose of 40mg Venetoclax: in a daily ramp-up strategy (100 mg d4, 200 mg d5, 400 mg d6-17) Dexamethasone: intravenously 10mg, d1-14, 5mg, d15-28

Trial Locations (1)

710032

RECRUITING

Department of Hematology, Xijing Hospital, Fourth Military Medical University, Xi'an

All Listed Sponsors
lead

Xijing Hospital

OTHER